We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SIGMA ALDRICH CORP.

Sigma-Aldrich is a life science and high technology company that develops, manufactures, purchases, and distributes v... read more Featured Products: More products

Download Mobile App




Plasma Cytokine Responses Characterized in Melioidosis

By LabMedica International staff writers
Posted on 04 Dec 2019
Melioidosis, an infectious disease caused by the environmental saprophyte Burkholderia pseudomallei, is endemic across many areas of Southeast Asia, South Asia, Northern Australia and America. More...
B. pseudomallei is a facultative intracellular bacterium, a characteristic that contributes to its pathogenesis and persistence in the host and that may modulate the cytokine response to infection.

Patients may present with a wide range of clinical manifestations including pneumonia, bacteremia, abscesses, and sepsis, frequently leading to multiorgan failure and eventually death. The immunological markers and pathways that identify patients at risk of death in melioidosis are not well understood. Several immune cells including macrophages, natural killer (NK) cells, NK T cells, and T cells respond to bacterial infection rapidly by generation of several potent cytokines.

Microbiologists and immunologists at the Mahidol University (Bangkok, Thailand) conducted a prospective longitudinal study in two hospitals in Northeast Thailand to enroll 161 melioidosis patients, 13 uninfected healthy controls, and 11 uninfected diabetic controls. Blood was obtained from all individuals at enrollment (day 0) and at days 5, 12, and 28 from surviving melioidosis patients. IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and TNF-α were assayed in plasma. These were determined in human plasma samples using bead-based multiplex assays of Luminex technology (MILLIPLEX MAP kit: HSTCMAG-28K-12 plex, Millipore, Billerica, MA, USA). The association of each cytokine and its dynamics with 28-day mortality was determined.

The investigators reported that of melioidosis patients, 131/161 (81%) were bacteremic, and 68/161 (42%) died. On enrollment median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23, and TNF-α were higher in melioidosis patients compared with uninfected healthy controls and all but IFN-γ were positively associated with 28-day mortality. IL-8 provided the best discrimination of mortality. Over time, non-survivors had increasing IL-6, IL-8, and IL-17A levels, in contrast to survivors. In joint modeling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10, and TNF-α predicted survival.

The authors concluded that in a severely ill cohort of melioidosis patients, specific pro- and anti-inflammatory and Th17 cytokines were associated with survival from melioidosis, at enrollment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis. The study was published on November 7, 2019 in the journal Clinical Microbiology and Infection.

Related Links:
Mahidol University
Millipore



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.